Get the Stockscreener App
0.9001
8.00%
-0.0783
Renovorx Inc stock is traded at $0.9001, with a volume of 147.39K.
It is down -8.00% in the last 24 hours and up +5.31% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$0.9784
Open:
$0.97
24h Volume:
147.39K
Relative Volume:
0.49
Market Cap:
$32.98M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-1.5791
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
-13.45%
1M Performance:
+5.31%
6M Performance:
-29.13%
1Y Performance:
-31.55%
1-Day Range:
$0.89
$0.9779
1-Week Range:
$0.89
$1.065
52-Week Range:
$0.7006
$1.50
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.90 | 35.86M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.09 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
866.10 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.40 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Renovorx Inc Stock (RNXT) Latest News
Agah Ramtin, chief medical officer at RenovoRx, buys $9975 in shares By Investing.com - Investing.com Nigeria
Agah Ramtin, chief medical officer at RenovoRx, buys $9975 in shares - Investing.com India
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center - Investing News Network
RenovoRx Reports Growing Adoption of RenovoCath Device by U.S. Cancer Centers, Enhancing Targeted Oncology Treatment - Quiver Quantitative
RenovoRx, Inc. Expands RenovoCath®? Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center - marketscreener.com
Loss-Making RenovoRx, Inc. (NASDAQ:RNXT) Expected To Breakeven In The Medium-Term - Yahoo Finance
Dividend Watch: Will RenovoRx Inc outperform tech stocks2025 Major Catalysts & High Accuracy Investment Signals - baoquankhu1.vn
Jobs Data: Is RenovoRx Inc stock a value trapTrade Volume Summary & Real-Time Volume Triggers - baoquankhu1.vn
Gap Down: Will RenovoRx Inc benefit from rate cuts2025 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
Bear Alert: What is RenovoRx Incs book value per share2025 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Pullback Watch: Will RenovoRx Inc outperform its industry peersJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 - Investing News Network
RenovoRx CEO to Provide Update on Targeted Oncology Therapies at AlphaNorth Capital Event - Quiver Quantitative
Market Fear: Can RenovoRx Inc expand its profit marginsWeekly Market Outlook & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Setups: Should value investors consider RenovoRx IncJuly 2025 Update & Safe Capital Growth Stock Tips - baoquankhu1.vn
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates - MSN
How RenovoRx Inc. stock reacts to inflationary pressuresEarnings Miss & Reliable Intraday Trade Plans - ulpravda.ru
Will RenovoRx Inc. stock deliver better than expected guidanceJuly 2025 Setups & Long-Term Capital Growth Strategies - ulpravda.ru
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - The Manila Times
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026 - Sahm
Will RenovoRx Inc. stock reach all time highs in 20252025 Market Outlook & Low Risk High Win Rate Picks - Улправда
Is RenovoRx Inc. stock resilient to inflationJuly 2025 Momentum & Capital Protection Trade Alerts - ulpravda.ru
How sustainable is RenovoRx Inc. stock dividend payout2025 Risk Factors & Weekly High Potential Stock Alerts - Улправда
Investor Mood: Will RenovoRx Inc stock see PE expansionMarket Sentiment Report & Real-Time Buy Zone Alerts - moha.gov.vn
Can RenovoRx Inc. stock continue upward trendTrade Risk Assessment & Growth Focused Stock Pick Reports - ulpravda.ru
Will RenovoRx Inc. stock see PE expansionShort Setup & Free Weekly Chart Analysis and Trade Guides - Улправда
RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 - Investing News Network
New study aims to make pancreatic cancer chemo hit tumors, not the whole body - Stock Titan
RenovoRx (NASDAQ:RNXT) Stock Price Down 1% – Here’s Why - Defense World
Will RenovoRx Inc. stock pay special dividends2026 world cup usa national team quarterfinals defensive leaders high defensive line knockout prediction expert opinion - ulpravda.ru
RenovoRx receives Nasdaq notice for bid price noncompliance - MSN
RenovoRx Receives Nasdaq Notice for Bid Price Noncompliance - TipRanks
RenovoRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Aug Opening: How RenovoRx Inc stock responds to policy changesQuarterly Profit Summary & Smart Swing Trading Techniques - Bộ Nội Vụ
Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 By Investing.com - Investing.com Australia
Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 - Investing.com India
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength - Nasdaq
Is RenovoRx Inc. stock attractive for growth ETFsJuly 2025 Setups & Free Long-Term Investment Growth Plans - Улправда
RenovoRx's Differentiated Targeted Drug Delivery Platform Addresses Hypovascular Cancers - Smartkarma
How RenovoRx Inc. stock performs during Fed tightening cyclesIndex Update & Safe Capital Growth Stock Tips - Улправда
How RenovoRx Inc. stock responds to policy changesJuly 2025 Retail & Capital Efficient Trade Techniques - DonanımHaber
CEO Bagai Buys 5,000 ($4.3K) Of RenovoRx Inc [RNXT] - TradingView — Track All Markets
Why RenovoRx Inc. stock could outperform in 2025Trade Risk Report & Short-Term High Return Strategies - DonanımHaber
RenovoRx Earnings Notes - Trefis
RenovoRx Executive Makes a Significant Stock Purchase! - TipRanks
Chmn Agah Buys 12,000 ($10.2K) Of RenovoRx Inc [RNXT] - TradingView — Track All Markets
RenovoRx CMO Ramtin Agah Buys 12,000 Shares - TradingView — Track All Markets
RenovoRx, Inc. (RNXT) CMO-director purchases 12,000 shares at $0.85 - Stock Titan
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 - Investing News Network
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO GI 2026 on Innovative Targeted Therapy for Pancreatic Cancer - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) to Present TIGeR-PaC PK/PD Data at ASCO GI Symposium 2026 - Stock Titan
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):